Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP: Sivelestat Sodium for Post-operative Organ Dysfunction in Aortic Dissection
NCT07156656Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sivelestat in Acute Type A Aortic Dissection (ATAAD) and organ dysfunction (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Change in SOFA Score from Baseline to Day 5. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
Acute Type A Aortic Dissection (ATAAD)organ dysfunction
Beyond the preview
Go deeper on NCT07156656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156656.